Cancer immune escape: MHC expression in primary tumours versus metastases

The functional role of integrins during intra- and extravasation within the metastatic cascade

(2019) Greta Sökeland et al.   Molecular Cancer

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses

(2018) Natalia Aptsiauri et al.   CURRENT OPINION IN IMMUNOLOGY

Author Correction: The landscape of genomic alterations across childhood cancers

(2018) Susanne N. Gröbner et al.   NATURE

Type I Interferon in Chronic Virus Infection and Cancer

(2017) Laura M. Snell et al.   TRENDS IN IMMUNOLOGY

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

(2017) Antje Sucker et al.   Nature Communications

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting

(2017) Kazuyoshi Takeda et al.   Nature Communications

Rejection versus escape: the tumor MHC dilemma

(2016) Federico Garrido et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration

(2016) Francisco Perea et al.   INTERNATIONAL JOURNAL OF CANCER

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

(2014) L. Robert et al.   CLINICAL CANCER RESEARCH

Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype

(2014) Federico Garrido et al.   INTERNATIONAL JOURNAL OF CANCER

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response

(2014) P. Kvistborg et al.   Science Translational Medicine

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

(2013) Ana B. del Campo et al.   INTERNATIONAL JOURNAL OF CANCER

Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

(2012) Monica Bernal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeting HLA class I expression to increase tumor immunogenicity

(2012) A. B. del Campo et al.   TISSUE ANTIGENS

Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma

(2011) Madhavi Challa-Malladi et al.   CANCER CELL

Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes

(2011) Rafael Carretero et al.   INTERNATIONAL JOURNAL OF CANCER

The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions

(2010) Federico Garrido et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy

(2010) Federico Garrido et al.   INTERNATIONAL JOURNAL OF CANCER

Immune evasion of microsatellite unstable colorectal cancers

(2010) Matthias Kloor et al.   INTERNATIONAL JOURNAL OF CANCER

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

(2008) Natalia Aptsiauri et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

(2008) Rafael Carretero et al.   IMMUNOGENETICS

The immunologic constant of rejection

(2008) Ena Wang et al.   TRENDS IN IMMUNOLOGY